Directly Observed antiretroviral Therapy for people living with Human Immunodeficiency Virus (HIV) and Acquired ImmunDeficiency Syndrome (AIDS): a randomised controlled trial

Submission date	Recruitment status	Prospectively registered
01/01/2004	No longer recruiting	☐ Protocol
Registration date	Overall study status	Statistical analysis plan
02/03/2004	Completed	Results
Last Edited	Condition category	Individual participant data
06/11/2009	Infections and Infestations	Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Ricardo Kuchenbecker

Contact details

Rua Landel de Moura, 1369 Porto Alegre Brazil 91920-150 +55 51 32688919 rsk@via-rs.net

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

Study information

Scientific Title

Acronym

DOT-AIDS

Study objectives

Not provided at time of registration

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

HIV/AIDS

Interventions

Intervention group:

Twice-weekly home visits performed by community-peer educators over a two month period. Thereafter, patients were visited once a week for four months. The purpose of the peer educators was to assist the patients in taking medication and provide information and support related to adherence, the importance of following physician recommendations and information related to healthy behaviour (e.g. safe sex, supportive measures related to stigma, and adherence strategies).

Control group:

Usual care provided by the outpatient clinics.

Intervention Type

Other

Phase

Not Specified

Primary outcome measure

- 1. Adherence to highly active antiretroviral therapy (HAART) at the end of the study (6 months)
- 2. Diseases progression
- 3. Occurence of AIDS-related disease/opportunistic infections

Secondary outcome measures

Not provided at time of registration

Overall study start date

01/01/2004

Completion date

31/12/2004

Eligibility

Key inclusion criteria

- 1. HIV-1 infected individuals
- 2. 18 years old or older
- 3. Starting antiretroviral therapy in three AIDS clinics in Porto Alegre (Brazil)

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Not Specified

Target number of participants

Not provided at time of registration

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/01/2004

Date of final enrolment

31/12/2004

Locations

Countries of recruitment

Brazil

Study participating centre Rua Landel de Moura, 1369

Porto Alegre Brazil 91920-150

Sponsor information

Organisation

Ministry of Health (Brazil)

Sponsor details

Ministério da Saúde Secretaria de Políticas de Saúde Coordenação Nacional de DST e Aids Grupo Matricial de Pesquisa e Vacinas W3 Norte - SEPN 511 - Bloco C Brasilia Brazil 70750-537 +55-51-4488121 aids@aids.gov.br

Sponsor type

Government

Website

http://portal.saude.gov.br/portal/saude/default.cfm

ROR

https://ror.org/02y7p0749

Funder(s)

Funder type

Government

Funder Name

Ministry of Health (Brazil)

Results and Publications

Publication and dissemination planNot provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration